Immunology Collaboration and Licensing Agreements Trends Report 2024: Explore 862 Detailed Contract Documents via SEC Submissions - Access Deal Payment Terms and Trigger Clauses
14. Oktober 2024 06:46 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Global Systemic Sclerosis (Scleroderma) Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
31. Mai 2024 04:34 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The...
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
16. Mai 2024 10:45 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027
30. Januar 2024 20:25 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global scleroderma market is poised for...
Scleroderma Therapeutics Market is estimated to be US$ 4.3 Billion by 2032; Growing Incidence and Screening Rates of Scleroderma to Fuel-By PMI
18. September 2023 13:30 ET
|
PMI
Covina, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Scleroderma, also known as systemic sclerosis, is a rare and chronic autoimmune disease that primarily affects the connective tissues in the body. There...
Autoimmune Disease Testing Market is set to reach revenue of US$ 15.75 Billion, expected to grow at 10% CAGR during 2023 to 2033 period | Future Market Insights, Inc.
10. April 2023 03:55 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 10, 2023 (GLOBE NEWSWIRE) -- According to FMI estimations, the Autoimmune Disease Testing Market could increase from US$ 6.07 billion in 2023 to US$ 15.75 billion by 2033. The...
AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients
26. Juli 2022 17:50 ET
|
Aisa Pharma, Inc.
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30. März 2022 08:00 ET
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
12. Januar 2022 07:30 ET
|
APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
14. August 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...